Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Obinutuzumab vs FCR/BR in Fit, Previously Untreated CLL without del(17p) or TP53 Mutation
2023-504036-17-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Roche. Primary endpoint: Minimal residual disease (MRD) response rate in peripheral blood at Month 15. Started Jul 2024; status: completed.
02
Drugs
venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-504036-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504036-17-00.